Cancer Clinical Trials with David Cosgrove, MD

In this episode, host Shikha Jain, MD, speaks with David Cosgrove, MD, about implementing real-world utilization of clinical trials, the importance of diversity in clinical trials and more.

•    Welcome to another exciting episode of Oncology Overdrive 1:17
•    About Cosgrove 1:26
•    The interview 2:54
•    How did you make your way from Ireland to Portland, Oregon?  3:18
•    As a fellow GI oncologist, what are you excited about in the cancer research space?  6:13
•    How can we realistically address disparities in cancer care to deliver the latest breakthroughs to patients?  8:54
•    Jain and Cosgrove on the challenges GI cancers experience in terms of delivery of cancer care compared to colleagues in other spaces. 11:22
•    What excites you about what’s happening in oncology right now, and where we’re going in this space? 13:30
•    How did you end up as medical director at Compass Oncology?  15:15
•    What are you specifically working on now, and where do you hope to see it go in the next five years?  17:25
•    How do we get more patients from different backgrounds into clinical trials, and why is it important that we do that? 19:05
•    Jain and Cosgrove on challenges facing patient guidelines and qualifications for clinical trials. 21:09
•    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 23:41
•    How to contact Cosgrove 24:45
•    Thanks for listening 25:49

David Cosgrove, MD, serves as the medical director of Compass Oncology in Portland, Oregon, and specializes in general adult oncology with advanced subspecialty expertise in gastrointestinal cancers.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Cosgrove can be reached via email [email protected].
 
Disclosures: Jain and Cosgrove report no relevant financial disclosures.